Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

The addition of a sagittal image fusion improves the prostate cancer detection in a sensor-based MRI /ultrasound fusion guided targeted biopsy.

Günzel K, Cash H, Buckendahl J, Königbauer M, Asbach P, Haas M, Neymeyer J, Hinz S, Miller K, Kempkensteffen C.

BMC Urol. 2017 Jan 13;17(1):7. doi: 10.1186/s12894-016-0196-9.

2.

The Effect of Evolving Strategies in the Surgical Management of Organ-Confined Prostate Cancer: Comparison of Data from 2005 to 2014 in a Multicenter Setting.

Pohle M, Magheli A, Fischer T, Kempkensteffen C, Busch J, Cash H, Miller K, Hinz S.

Adv Ther. 2017 Jan 4. doi: 10.1007/s12325-016-0469-4. [Epub ahead of print]

PMID:
28054309
3.

Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus.

Maxeiner A, Magheli A, Jöhrens K, Kilic E, Braun TL, Kempkensteffen C, Hinz S, Stephan C, Miller K, Busch J.

BJU Int. 2016 Nov;118(5):750-757. doi: 10.1111/bju.13451.

PMID:
26915345
4.

Prevalence of Late-Onset Hypogonadism in Men with Localized and Metastatic Renal Cell Carcinoma.

Ralla B, Magheli A, Wolff I, Erber B, Goranova I, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Busch J.

Urol Int. 2016 Oct 13. [Epub ahead of print]

PMID:
27732978
5.

Predictive Parameters Identifying Men Eligible for a Sole MRI/Ultrasound Fusion-Guided Targeted Biopsy without an Additional Systematic Biopsy.

Günzel K, Haas M, Maxeiner A, Stephan C, Buckendahl J, Asbach P, Miller K, Kempkensteffen C, Cash H.

Urol Int. 2017;98(1):15-21. doi: 10.1159/000449258.

PMID:
27618633
6.

Long-Term Donor Outcomes after Pure Laparoscopic versus Open Living Donor Nephrectomy: Focus on Pregnancy Rates, Hypertension and Quality of Life.

Friedersdorff F, Kothmann L, Manus P, Roigas J, Kempkensteffen C, Magheli A, Busch J, Liefeldt L, Giessing M, Deger S, Schostak M, Miller K, Fuller TF.

Urol Int. 2016;97(4):450-456.

7.

Outcome of Patients after Third and Fourth Kidney Transplantation.

Friedersdorff F, Patabendhi S, Busch J, Kempkensteffen C, Halleck F, Fuller TF, Miller K, Peters R.

Urol Int. 2016;97(4):445-449.

PMID:
27310597
8.

Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma.

Ralla B, Erber B, Goranova I, Klooker A, Maxeiner A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J.

Urol Int. 2016 Mar 11. [Epub ahead of print]

PMID:
26963286
9.

Dynamics of Urinary Calprotectin after Renal Ischaemia.

Ebbing J, Seibert FS, Pagonas N, Bauer F, Miller K, Kempkensteffen C, Günzel K, Bachmann A, Seifert HH, Rentsch CA, Ardelt P, Wetterauer C, Amico P, Babel N, Westhoff TH.

PLoS One. 2016 Jan 8;11(1):e0146395. doi: 10.1371/journal.pone.0146395.

10.

Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis.

Ralla B, Erber B, Goranova I, von der Aue L, Floercken A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J.

World J Urol. 2016 Aug;34(8):1147-54. doi: 10.1007/s00345-015-1740-z.

PMID:
26676614
11.

Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer.

Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T.

J Urol. 2016 Apr;195(4 Pt 1):1120-5. doi: 10.1016/j.juro.2015.09.084.

PMID:
26454102
12.

Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.

Cash H, Günzel K, Maxeiner A, Stephan C, Fischer T, Durmus T, Miller K, Asbach P, Haas M, Kempkensteffen C.

BJU Int. 2016 Jul;118(1):35-43. doi: 10.1111/bju.13327.

PMID:
26384851
13.

The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.

Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, Asbach P, Haas M, Hinz S, Neymeyer J, Miller K, Günzel K, Kempkensteffen C.

World J Urol. 2016 Apr;34(4):525-32. doi: 10.1007/s00345-015-1671-8.

PMID:
26293117
14.

Optimizing scintigraphic evaluation of split renal function in living kidney donors using the geometric mean method: a preliminary retrospective study.

Weinberger S, Baeder M, Scheurig-Muenkler C, Steffen IG, Magheli A, Miller K, Kempkensteffen C.

J Nephrol. 2016 Jun;29(3):435-41. doi: 10.1007/s40620-015-0223-z.

PMID:
26286903
15.

Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.

Aziz A, Kempkensteffen C, May M, Lebentrau S, Burger M, Chun FK, Brookman-May S.

Expert Rev Anticancer Ther. 2015 Jun;15(6):649-66. doi: 10.1586/14737140.2015.1038247. Review.

PMID:
25905802
16.

[Malignant Sertoli cell tumors of the testes].

Günzel K, Wegner H, Cash H, Lohneis P, Kempkensteffen C, Miller K, Hinz S.

Urologe A. 2015 Aug;54(8):1115-7. doi: 10.1007/s00120-015-3814-3. German.

PMID:
25821170
17.

Evaluation of perioperative complications in open and laparoscopic surgery for renal cell cancer with tumor thrombus involvement using the Clavien-Dindo classification.

Ebbing J, Wiebach T, Kempkensteffen C, Miller K, Bachmann A, Günzel K, Rieken M, Friedersdorff F, Baumunk D, Weikert S.

Eur J Surg Oncol. 2015 Jul;41(7):941-52. doi: 10.1016/j.ejso.2015.02.009.

PMID:
25817982
18.

[Propensity score comparison of the various radical surgical techniques for high-risk prostate cancer].

Busch J, Gonzalgo M, Leva N, Ferrari M, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Magheli A.

Aktuelle Urol. 2015 Jan;46(1):45-51. doi: 10.1055/s-0034-1395562. German.

PMID:
25526221
19.

Matched comparison of robot-assisted, laparoscopic and open radical prostatectomy regarding pathologic and oncologic outcomes in obese patients.

Busch J, Gonzalgo ML, Leva N, Ferrari M, Cash H, Kempkensteffen C, Hinz S, Miller K, Magheli A.

World J Urol. 2015 Mar;33(3):397-402. doi: 10.1007/s00345-014-1326-1.

PMID:
24853030
20.

An epigenetic screen unmasks metallothioneins as putative contributors to renal cell carcinogenesis.

Alkamal I, Ikromov O, Tölle A, Fuller TF, Magheli A, Miller K, Krause H, Kempkensteffen C.

Urol Int. 2015;94(1):99-110. doi: 10.1159/000357282.

PMID:
24662736
Items per page

Supplemental Content

Loading ...
Support Center